#44: Obesity Medication Overview from AACE 2017
Published June 19, 2017
54 min
    Add to queue
    Copy URL
    Show notes

    Master the safe and effective use of obesity medications with Endocrinologist, Dr. Karl Nadolsky (co-author of 2016 AACE Obesity guidelines), Director of the Diabetes, Obesity & Metabolic Institute at Walter Reed National Military Medical Center. We get under the hood of each FDA approved obesity medication plus some of our normal hijinks. Check out episode #23 for a more general overview of obesity.

    Full show notes available at http://thecurbsiders.com/podcast

    Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com.

    Time Stamps

    00:00 Intro

    03:12 Picks of the week

    08:44 Rapid fire questions

    13:00 Counsel patients about obesity

    14:40 Pathophysiology of obesity

    18:00 Case

    22:46 Phentermine/topiramate (Qsymia)

    26:20 Bupropion/naltrexone (Contrave)

    29:18 Liraglutide (Saxenda)

    34:32 Orlistat (Alli, Xenical)

    37:35 Cost issues

    40:18 Lifelong medical therapy for obesity

    42:44 Dr. Nadolsky’s take home points

    44:45 The Curbsiders recap and discuss their experience with obesity medications

    52:28 Outro

    Tags: assistant, care, doctor, education family, foam, foamed, health, hospitalist, hospital, internal, internist, nurse, medicine, medical, physician, practitioner, primary, resident, student, obesity, pharmacotherapy, weight loss, safety, side effects, orlistat, alli, naltrexone, bupropion, contrave, phentermine, topiramate, qsymia, lorcaserin, belviq, FDA

        0:00:00 / 0:00:00